Meningioma

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 2, 2008, Pages 153-171

  Marosi, Christine ^a   Hassler, Marco ^a   Roessler, Karl ^a   Reni, Michele ^b   Sant, Milena ^c   Mazza, Elena ^b   Vecht, Charles ^d  

^a UNIVERSITY OF VIENNA   (Austria)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Neurology Medical Center   (Netherlands)

Author keywords

Meningioma; Risk factors; Standard therapy

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; HYDROXYUREA; INTERFERON; OCTREOTIDE; ONCOSTATIN M; PROGESTERONE RECEPTOR; TRAPIDIL;

ARTIFICIAL EMBOLISM; BLOOD TOXICITY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CYTOLOGY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE DELETION; HEAD INJURY; HISTOPATHOLOGY; HUMAN; IONIZING RADIATION; LEUKOPENIA; MENINGIOMA; MENTAL DISEASE; NEUTROPENIA; PROGNOSIS; REVIEW; STEREOTACTIC RADIOSURGERY;

COMBINED MODALITY THERAPY; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS;

EID: 45949098435     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.01.010     Document Type: Review

References (184)

1. Louis D.N., Scheithauer B.W., Budka H., von Deimling A., and Kepes J.J. Meningiomas. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and genetics. Tumours of the nervous system, WHO classification of tumors (2000), IARC Press, Lyon 176-184
2. Rohringer M., Sutherland G.R., Louw D.F., and Sima A.A. Incidence and clinicopathological features of meningioma. J Neurosurg 71 (1989) 665-672
3. Rausing A., Ybo W., and Stenflo J. Intracranial meningioma-a population study of 10 years. Acta Neurol Scand 46 (1970) 102-110
4. Lantos P., van den Berg S.R., and Kleihues P. Tumours of the nervous system. In: Graham D.I., and Lantos P.L. (Eds). Greenfield's neuropathology. 6th ed. (1996), Arnold, London 583-879
5. Longstreth W.T., dennis L.K., McGuire V.M., Drangsholt M.T., and Koepsell T.D. Epidemiology of intracranial meningioma. Cancer 72 (1993) 639-648
6. Pobereskin L.H., and Chadduck J.B. Incidence of brain tumours in two English counties: a population-based study. J Neurol Neurosurg Psychiatry 69 (2000) 464-471
7. Christensen H.C., Kosteljanetz M., and Johansen C. Incidences of gliomas and meningiomas in Denmark, 1943-1997. Neurosurgery 52 (2003) 1327-1333
8. Jaaskelainen J., Haltia M., Laasonen E., Wahlstrom T., and Valtonen S. The growth rate of intracranial meningiomas and its relation to histology. An analysis of 43 patients. Surg Neurol 24 (1985) 165-172
9. Zwerdling T., and Dothage J. Meningiomas in children and adolescents. J Pediatr Hematol Oncol 24 (2002) 199-204
10. Rushing E.J., Olsen C., Mena H., et al. Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg 103 (2005) 489-495
11. Sadetzki S., Flint-Richter P., Ben Tal T., and Nass D. Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 97 (2002) 1078-1082
12. Strojan P., Popovic M., and Jereb B. Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature. Int J Radiat Oncol Biol Phys 48 (2000) 65-73
13. Preston D.L., Ron E., Yonehara S., et al. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst 94 (2002) 1555-1563
14. Bondy M., and Ligon B.L. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 29 (1996) 197-205
15. Rodvall Y., Ahlbom A., Pershagen G., Nylander M., and Spannare B. Dental radiography after age 25 years, amalgam fillings and tumours of the central nervous system. Oral Oncol 34 (1998) 265-269
16. Hardell L., Carlberg M., and Hansson M.K. Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology 25 (2005) 120-128
17. Hardell L., Carlberg M., and Hansson M.K. Pooled analysis of two case-control studies on the use of cellular and cordless telephones and the risk of benign brain tumours diagnosed during 1997-2003. Int J Oncol 28 (2006) 509-518
18. Christensen H.C., Schuz J., Kosteljanetz M., et al. Cellular telephones and risk for brain tumors: a population-based, incident case-control study. Neurology 64 (2005) 1189-1195
19. Lonn S., Ahlbom A., Hall P., and Feychting M. Long-term mobile phone use and brain tumor risk. Am J Epidemiol 161 (2005) 526-535
20. Schuz J., Bohler E., Berg G., et al. Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany). Am J Epidemiol 163 (2006) 512-520
21. Klaeboe L., Lonn S., Scheie D., et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. Int J Cancer 20 117 (2005) 996-1001
22. Annegers J.F., Laws Jr. E.R., Kurland L.T., and Grabow J.D. Head trauma and subsequent brain tumors. Neurosurgery 4 (1979) 203-206
23. Preston-Martin S., and White S.C. Brain and salivary gland tumors related to prior dental radiography: implications for current practice. J Am Dent Assoc 120 (1990) 151-158
24. Phillips L.E., Koepsell T.D., van Belle G., et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology 58 (2002) 1849-1852
25. Michael D.B., Byers D.M., and Irwin L.N. Gene expression following traumatic brain injury in humans: analysis by microarray. J Clin Neurosci 12 (2005) 284-290
26. Korhonen K., Salminen T., Raitanen J., et al. Female predominance in meningiomas cannot be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80 (2006) 1-7
27. Inoue T., Akahira J., Suzuki T., et al. Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 87 (2002) 5325-5331
28. Strik H.M., Strobelt I., Pietsch-Breitfeld B., et al. The impact of progesterone receptor expression on relapse in the long-term clinical course of 93 benign meningiomas. In Vivo 16 (2002) 265-270
29. Nagashima G., Asai J., Suzuki R., and Fujimoto T. Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression. Brain Tumor Pathol 18 (2001) 1-5
30. Custer B., Longstreth Jr. W.T., Phillips L.E., Koepsell T.D., and van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6 (2006) 152.:152
31. Maiuri F., Cappabianca P., Iaconetta G., and D'Acunzi G. Meningiomas associated with brain metastases. Zentralbl Neurochir 63 (2002) 111-115
32. Markopoulos C., Sampalis F., Givalos N., and Gogas H. Association of breast cancer with meningioma. Eur J Surg Oncol 24 (1998) 332-334
33. Aghi M., Kiehl T.R., and Brisman J.L. Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature. J Neurooncol 75 (2005) 149-155
34. Caroli E., Salvati M., Giangaspero F., Ferrante L., and Santoro A. Intrameningioma metastasis as first clinical manifestation of occult primary breast carcinoma. Neurosurg Rev 29 (2006) 49-54
35. Schneider B., Pulhorn H., Rohrig B., and Rainov N.G. Predisposing conditions and risk factors for development of symptomatic meningioma in adults. Cancer Detect Prev 29 (2005) 440-447
36. Talback M., Stenbeck M., and Rosen M. Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data. Eur J Cancer 40 (2004) 1361-1372
37. Nakamura M., Roser F., Michel J., Jacobs C., and Samii M. Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas. Zentralbl Neurochir 66 (2005) 17-23
38. Yano S., and Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 105 (2006) 538-543
39. Sankila R., Kallio M., Jaaskelainen J., and Hakulinen T. Long-term survival of 1986 patients with intracranial meningioma diagnosed from 1953 to 1984 in Finland. Comparison of the observed and expected survival rates in a population-based series. Cancer 70 (1992) 1568-1576
40. Bateman B.T., Pile-Spellman J., Gutin P.H., and Berman M.F. Meningioma resection in the elderly: nationwide inpatient sample, 1998-2002. Neurosurgery 57 (2005) 866-872
41. Curry W.T., McDermott M.W., Carter B.S., and Barker F.G. Craniotomy for meningioma in the United States between 1988 and 2000: decreasing rate of mortality and the effect of provider caseload. J Neurosurg 102 (2005) 977-986
42. Berrino F., Capocaccia R., Coleman M.P., et al. Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 14 Suppl 5 (2003)
43. Maier H., Ofner D., Hittmair A., Kitz K., and Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 77 (1992) 616-623
44. Takahashi J.A., Ueba T., Hashimoto N., Nakashima Y., and Katsuki N. The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg Neurol 61 (2004) 149-155
45. Konstantinidou A.E., Korkolopoulou P., Mahera H., et al. Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43 (2003) 280-290
46. Leuraud P., Dezamis E., Aguirre-Cruz L., et al. Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 100 (2004) 303-309
47. Mihaila D., Jankowski M., Gutierrez J.A., et al. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 9 (2003) 4443-4451
48. Maillo A., Orfao A., Sayagues J.M., et al. New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol 21 (2003) 3285-3295
49. Kleihues P., Burger P.C., and Scheithauer B.W. Histological typing of tumours of the central nervous system. In: Kleihues P., and Webster K.C. (Eds). Pathology and genetics, tumours of the nervous system, WHO classification of tumours. 2nd ed. (1993), Springer-Verlag, Berlin, Germany
50. Kleihues P., Burger P.C., and Scheithauer BW. Histological typing of tumours of the central nervous system (International Histological Classification of Tumours). Book (2000)
51. Perry A., Scheithauer B.W., Stafford S.L., Lohse C.M., and Wollan P.C. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85 (1999) 2046-2056
52. van Tilborg A.A., Al Allak B., Velthuizen S.C., et al. Chromosomal instability in meningiomas. J Neuropathol Exp Neurol 64 (2005) 312-322
53. Kros J.M., and Wolbers J.G. Meningiomas: prognostic relevance of histopathologic and genetic markers. Ned Tijdschr Geneeskd 145 (2001) 2160-2165
54. Wada K., Maruno M., Suzuki T., et al. Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray. Neurol Res 27 (2005) 747-754
55. Weber R.G., Bostrom J., Wolter M., et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94 (1997) 14719-14724
56. Espinosa A.B., Tabernero M.D., Maillo A., et al. The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res 12 (2006) 772-780
57. Tabernero M.D., Espinosa A.B., Maillo A., et al. Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: correlation with clinical, histopathologic, and prognostic features. Am J Clin Pathol 123 (2005) 744-751
58. Perry A., Stafford S.L., Scheithauer B.W., Suman V.J., and Lohse C.M. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82 (1998) 2262-2269
59. Cerda-Nicolas M., Lopez-Gines C., Perez-Bacete M., Barcia-Salorio J.L., and Llombart-Bosch A. Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: a study of 60 tumors. Clin Neuropathol 19 (2000) 259-267
60. Roessler K., Gatterbauer B., and Kitz K. Topoisomerase II alpha as a reliable proliferation marker in meningiomas. Neurol Res 24 (2002) 241-243
61. Korshunov A., Shishkina L., and Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Arch Pathol Lab Med 126 (2002) 1079-1086
62. Konstantinidou A.E., Korkolopoulou P., Kavantzas N., et al. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Histol Histopathol 18 (2003) 67-74
63. Yoshioka H., Hama S., Taniguchi E., et al. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 85 (1999) 936-944
64. Christov C., Lechapt-Zalcman E., Adle-Biassette H., Nachev S., and Gherardi R.K. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas. Acta Neuropathol (Berl) 98 (1999) 414-420
65. Harland S.P., Kuc R.E., Pickard J.D., and Davenport A.P. Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery 43 (1998) 890-898
66. Cuevas I.C., Slocum A.L., Jun P., et al. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 65 (2005) 5070-5075
67. Hassounah M., Lach B., Allam A., et al. Benign tumors from the human nervous system express high levels of survivin and are resistant to spontaneous and radiation-induced apoptosis. J Neurooncol 72 (2005) 203-208
68. Johnson M.D., Federspiel C.F., Gold L.I., and Moses H.L. Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells. Am J Pathol 141 (1992) 633-642
69. Roessler K., Dietrich W., and Kitz K. Expression of BCL-2 oncoprotein on tumor cells and tumor-infiltrating lymphocytes (TIL) in meningiomas. Neurosurg Rev 22 (1999) 205-209
70. Nakatani K., Yoshimi N., Mori H., et al. The significant role of telomerase activity in human brain tumors. Cancer 80 (1997) 471-476
71. Wang J.L., Nister M., Hermansson M., Westermark B., and Ponten J. Expression of PDGF beta-receptors in human meningioma cells. Int J Cancer 46 (1990) 772-778
72. Johnson M.D., Woodard A., Kim P., and Frexes-Steed M. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 94 (2001) 293-300
73. Johnson M., and Toms S. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?. J Neuropathol Exp Neurol 64 (2005) 1029-1036
74. Johnson M.D., Okedli E., Woodard A., Toms S.A., and Allen G.S. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg 97 (2002) 668-675
75. Niedermayer I., Feiden W., Henn W., et al. Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol 56 (1997) 879-886
76. Hunt D.P., Freeman A., Morris L.S., et al. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg 16 (2002) 10-15
77. Okuducu A.F., Zils U., Michaelis S.A., Michaelides S., and von Deimling A. Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology 48 (2006) 836-845
78. Maes L., Lippens E., Kalala J.P., and de Ridder L. The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif 38 (2005) 3-12
79. Maes L., Kalala J.P., Cornelissen M., and de Ridder L. PCNA, Ki-67 and hTERT in residual benign meningiomas. In Vivo 20 (2006) 271-275
80. Loussouarn D., Brunon J., Avet-Loiseau H., Campone M., and Mosnier J.F. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study. Hum Pathol 37 (2006) 415-421
81. Oikonomou E., Machado A.L., Buchfelder M., and Adams E.F. Meningiomas expressing and responding to cholecystokinin (CCK). J Neurooncol 73 (2005) 199-204
82. Trinkaus M., Vranic A., Dolenc V.V., and Lah T.T. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers 20 (2005) 50-59
83. Sadetzki S., Flint-Richter P., Starinsky S., et al. Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev 14 (2005) 969-976
84. Bindal R., Goodman J.M., Kawasaki A., Purvin V., and Kuzma B. The natural history of untreated skull base meningiomas. Surg Neurol 59 (2003) 87-92
85. Solero C.L., Giombini S., and Morello G. Suprasellar and olfactory meningiomas. Report on a series of 153 personal cases. Acta Neurochir (Wien) 67 (1983) 181-194
86. Symon L., and Jakubowski J. Clinical features, technical problems, and results of treatment of anterior parasellar meningiomas. Acta Neurochir Suppl (Wien) 28 (1979) 367-370
87. Finn J.E., and Mount L.A. Meningiomas of the tuberculum sellae and planum sphenoidale. A review of 83 cases. Arch Ophthalmol 92 (1974) 23-27
88. Lieu A.S., and Howng S.L. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 38 (2000) 45-52
89. Bosnjak R., Derham C., Popovic M., and Ravnik J. Spontaneous intracranial meningioma bleeding: clinicopathological features and outcome. J Neurosurg 103 (2005) 473-484
90. Sakowitz O.W., Harting I., Kohlhof P., Unterberg A.W., and Steiner H.H. Acute haemorrhage into a microcystic meningioma leading to cerebral herniation. Br J Neurosurg 19 (2005) 260-264
91. Hodges F.J., and Meningiomas. Radiology: diagnosis-imaging-intervention. In: Taveras J.M., and Ferucci J.T. (Eds). Neuroradiology and radiology of the head and neck III (1989), JB Lippincott, Philadelphia
92. Rokni-Yazdi H., and Sotoudeh H. Prevalence of "dural tail sign" in patients with different intracranial pathologies. Eur J Radiol 60 (2006) 42-45
93. Elster A.D., Challa V.R., Gilbert T.H., Richardson D.N., and Contento J.C. Meningiomas: MR and histopathologic features. Radiology 170 (1989) 857-862
94. Yoshikawa T., Aoki S., Hori M., et al. Time-resolved two-dimensional thick-slice magnetic resonance digital subtraction angiography in assessing brain tumors. Eur Radiol 10 (2000) 736-744
95. Bitzer M., Klose U., Geist-Barth B., et al. Alterations in diffusion and perfusion in the pathogenesis of peritumoral brain edema in meningiomas. Eur Radiol 12 (2002) 2062-2076
96. Takeguchi T., Miki H., Shimizu T., et al. Prediction of tumor-brain adhesion in intracranial meningiomas by MR imaging and DSA. Magn Reson Med Sci 2 (2003) 171-179
97. Galanaud D., Nicoli F., Le Fur Y., et al. Contribution of magnetic resonance spectrometry to the diagnosis of intracranial tumors. Ann Med Interne (Paris) 153 (2002) 491-498
98. Majos C., Alonso J., Aguilera C., et al. Utility of proton MR spectroscopy in the diagnosis of radiologically atypical intracranial meningiomas. Neuroradiology 45 (2003) 129-136
99. Rutten I., Raket D., Francotte N., et al. Contribution of NMR spectroscopy to the differential diagnosis of a recurrent cranial mass 7 years after irradiation for a pediatric ependymoma. Childs Nerv Syst 22 (2006) 1475-1478
100. Dorenbeck U., Grunwald I.Q., Schlaier J., and Feuerbach S. Diffusion-weighted imaging with calculated apparent diffusion coefficient of enhancing extra-axial masses. J Neuroimaging 15 (2005) 341-347
101. Jun P., Garcia J., Tihan T., McDermott M.W., and Cha S. Perfusion MR imaging of an intracranial collision tumor confirmed by image-guided biopsy. AJNR Am J Neuroradiol 27 (2006) 94-97
102. Kimura H., Takeuchi H., Koshimoto Y., et al. Perfusion imaging of meningioma by using continuous arterial spin-labeling: comparison with dynamic susceptibility-weighted contrast-enhanced MR images and histopathologic features. AJNR Am J Neuroradiol 27 (2006) 85-93
103. Murakami M., Imahori Y., Kimura S., et al. Positron emission tomography elucidates transport system and tumor proliferation in meningiomas. Oncol Rep 14 (2005) 853-859
104. Dufour H., Muracciole X., Metellus P., et al. Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal?. Neurosurgery 48 (2001) 285-294
105. Lee J.Y., Niranjan A., McInerney J., et al. Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J Neurosurg 97 (2002) 65-72
106. Subach B.R., Lunsford L.D., Kondziolka D., Maitz A.H., and Flickinger J.C. Management of petroclival meningiomas by stereotactic radiosurgery. Neurosurgery 42 (1998) 437-443
107. McCutcheon I.E. The biology of meningiomas. J Neurooncol 29 (1996) 207-216
108. McCarthy B.J., Davis F.G., Freels S., et al. Factors associated with survival in patients with meningioma. J Neurosurg 88 (1998) 831-839
109. Debus J., Wuendrich M., Pirzkall A., et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 19 (2001) 3547-3553
110. Flickinger J.C., Kondziolka D., Maitz A.H., and Lunsford L.D. Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int J Radiat Oncol Biol Phys 56 (2003) 801-806
111. In: Al Mefty O. (Ed). Meningiomas (1991), Raven Press, New York
112. Wolbers J.G., Avezaat C.J., Nowak P.J., and Kros J.M. 'Benign' meningioma. Ned Tijdschr Geneeskd 145 (2001) 2153-2157
113. Braunstein J.B., and Vick N.A. Meningiomas: the decision not to operate. Neurology 48 (1997) 1459-1462
114. Ausman J.I. Meningiomas-the future: is 2020 here?. Surg Neurol 59 (2003) 140-141
115. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20 (1957) 2208-2213
116. Borovich B., Doron Y., Braun J., et al. Recurrence of intracranial meningiomas: the role played by regional multicentricity. Part 2. Clinical and radiological aspects. J Neurosurg 65 (1986) 168-171
117. Gay E., Vuillez J.P., Palombi O., et al. Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas. Neurosurgery 57 (2005) 107-113
118. Butte P.V., Pikul B.K., Hever A., et al. Diagnosis of meningioma by time-resolved fluorescence spectroscopy. J Biomed Opt 10 (2005) 064026
119. Shinoura N., Takahashi M., and Yamada R. Delineation of brain tumor margins using intraoperative sononavigation: implications for tumor resection. J Clin Ultrasound 34 (2006) 177-183
120. Schulder M., Salas S., Brimacombe M., et al. Cranial surgery with an expanded compact intraoperative magnetic resonance imager. Technical note. J Neurosurg 104 (2006) 611-617
121. Stafford S.L., Perry A., Suman V.J., et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73 (1998) 936-942
122. Perry A., Stafford S.L., Scheithauer B.W., Suman V.J., and Lohse C.M. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21 (1997) 1455-1465
123. Condra K.S., Buatti J.M., Mendenhall W.M., et al. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39 (1997) 427-436
124. D'Andrea G., Roperto R., Caroli E., Crispo F., and Ferrante L. Thirty-seven cases of intracranial meningiomas in the ninth decade of life: our experience and review of the literature. Neurosurgery 56 (2005) 956-961
125. Morales F., Maillo A., Diaz-Alvarez A., et al. Skull base meningiomas: a predictive system to know the extent of their surgical resection and patient outcome. Neurocirugia (Astur) 16 (2005) 477-485
126. Saberi H., Meybodi A.T., and Rezai A.S. Levine-Sekhar grading system for prediction of the extent of resection of cranial base meningiomas revisited: study of 124 cases. Neurosurg Rev 29 (2006) 138-144
127. Levine Z.T., Buchanan R.I., Sekhar L.N., Rosen C.L., and Wright D.C. Proposed grading system to predict the extent of resection and outcomes for cranial base meningiomas. Neurosurgery 45 (1999) 221-230
128. Ragel B., and Jensen R.L. New approaches for the treatment of refractory meningiomas. Cancer Control 10 (2003) 148-158
129. Rosen C.L., Ammerman J.M., Sekhar L.N., and Bank W.O. Outcome analysis of preoperative embolization in cranial base surgery. Acta Neurochir (Wien) 144 (2002) 1157-1164
130. Bendszus M., Martin-Schrader I., Schlake H.P., and Solymosi L. Embolisation of intracranial meningiomas without subsequent surgery. Neuroradiology 45 (2003) 451-455
131. Bendszus M., Monoranu C.M., Schutz A., et al. Neurologic complications after particle embolization of intracranial meningiomas. AJNR Am J Neuroradiol 26 (2005) 1413-1419
132. Bouchard J.J. Radiation therapy of tumors and diseases of the nervous system (1966), Lea & Febiger, Philadelphia
133. Mirimanoff R.O., Dosoretz D.E., Linggood R.M., Ojemann R.G., and Martuza R.L. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62 (1985) 18-24
134. Taylor Jr. B.W., Marcus Jr. R.B., Friedman W.A., Ballinger Jr. W.E., and Million R.R. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 15 (1988) 299-304
135. Goldsmith B.J., Wara W.M., Wilson C.B., and Larson D.A. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80 (1994) 195-201
136. Kondziolka D., Levy E.I., Niranjan A., Flickinger J.C., and Lunsford L.D. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg 91 (1999) 44-50
137. Noel G., Bollet M.A., Calugaru V., et al. Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. Int J Radiat Oncol Biol Phys 62 (2005) 1412-1422
138. Sajja R., Barnett G.H., Lee S.Y., et al. Intensity-modulated radiation therapy (IMRT) for newly diagnosed and recurrent intracranial meningiomas: preliminary results. Technol Cancer Res Treat 4 (2005) 675-682
139. Alheit H., Saran F.H., Warrington A.P., et al. Stereotactically guided conformal radiotherapy for meningiomas. Radiother Oncol 50 (1999) 145-150
140. Knoos T., Kristensen I., and Nilsson P. Volumetric and dosimetric evaluation of radiation treatment plans: radiation conformity index. Int J Radiat Oncol Biol Phys 42 (1998) 1169-1176
141. Maire J.P., Caudry M., Guerin J., et al. Fractionated radiation therapy in the treatment of intracranial meningiomas: local control, functional efficacy, and tolerance in 91 patients. Int J Radiat Oncol Biol Phys 33 (1995) 315-321
142. Milker-Zabel S., Zabel A., Schulz-Ertner D., et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys 61 (2005) 809-816
143. Brell M., Villa S., Teixidor P., et al. Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance. Surg Neurol 65 (2006) 28-33
144. Katz T.S., Amdur R.J., Yachnis A.T., Mendenhall W.M., and Morris C.G. Pushing the limits of radiotherapy for atypical and malignant meningioma. Am J Clin Oncol 28 (2005) 70-74
145. Kerty E. Optic nerve sheath meningeoma-from expectation to active treatment. Tidsskr Nor Laegeforen 125 (2005) 429-430
146. Richards J.C., Roden D., and Harper C.S. Management of sight-threatening optic nerve sheath meningioma with fractionated stereotactic radiotherapy. Clin Experiment Ophthalmol 33 (2005) 137-141
147. Berman D., and Miller N.R. New concepts in the management of optic nerve sheath meningiomas. Ann Acad Med Singapore 35 (2006) 168-174
148. Lomax N.J., and Scheib S.G. Quantifying the degree of conformity in radiosurgery treatment planning. Int J Radiat Oncol Biol Phys 55 (2003) 1409-1419
149. Pollock B.E., Stafford S.L., Utter A., Giannini C., and Schreiner S.A. Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small- to medium-size meningiomas. Int J Radiat Oncol Biol Phys 55 (2003) 1000-1005
150. Kim D.G., Kim C., Chung H.T., et al. Gamma knife surgery of superficially located meningioma. J Neurosurg 102 Suppl (2005) 255-258
151. Mindermann T., and de Rougemont O. The significance of tumor location for Gamma Knife treatment of meningiomas. Stereotact Funct Neurosurg 82 (2004) 194-195
152. Chang J.H., Chang J.W., Choi J.Y., Park Y.G., and Chung S.S. Complications after gamma knife radiosurgery for benign meningiomas. J Neurol Neurosurg Psychiatry 74 (2003) 226-230
153. Wellis G., Nagel R., Vollmar C., and Steiger H.J. Direct costs of microsurgical management of radiosurgically amenable intracranial pathology in Germany: an analysis of meningiomas, acoustic neuromas, metastases and arteriovenous malformations of less than 3 cm in diameter. Acta Neurochir (Wien) 145 (2003) 249-255
154. Maruyama K., Shin M., Kurita H., et al. Proposed treatment strategy for cavernous sinus meningiomas: a prospective study. Neurosurgery 55 (2004) 1068-1075
155. Edwards D.P., Leonhardt S.A., and Gass-Handel E. Novel mechanisms of progesterone antagonists and progesterone receptor. J Soc Gynecol Investig 7 (2000) S22-S24
156. Lamberts S.W., Tanghe H.L., Avezaat C.J., et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55 (1992) 486-490
157. Haak H.R., de Keizer R.J., Hagenouw-Taal J.C., et al. Successful mifepristone treatment of recurrent, inoperable meningioma. Lancet 336 (1990) 124-125
158. Newfield R.S., Spitz I.M., Isacson C., and New M.I. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 54 (2001) 399-404
159. Stewart D.J., Dahrouge S., Wee M., Aitken S., and Hugenholtz H. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neurooncol 24 (1995) 189-194
160. Cusimano M.D. Hydroxyurea for treatment of meningioma. J Neurosurg 88 (1998) 938-939
161. Newton H.B., Slivka M.A., and Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49 (2000) 165-170
162. Newton H.B., Scott S.R., and Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18 (2004) 495-499
163. Mason W.P., Gentili F., Macdonald D.R., et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97 (2002) 341-346
164. Rosenthal M.A., Ashley D.L., and Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci 9 (2002) 156-158
165. Hahn B.M., Schrell U.M., Sauer R., et al. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74 (2005) 157-165
166. Muhr C., Gudjonsson O., Lilja A., et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-l-methionine positron emission tomography. Clin Cancer Res 7 (2001) 2269-2276
167. Zhang Z.J., Muhr C., and Wang J.L. Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells. Anticancer Res 16 (1996) 717-723
168. Wober-Bingol C., Wober C., Marosi C., and Prayer D. Interferon-alfa-2b for meningioma. Lancet 345 (1995) 331
169. Zhang Z.J., Wang J.L., Muhr C., and Smits A. Synergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro. Cancer Lett 100 (1996) 99-105
170. Park K., Kim J.H., Nam D.H., et al. Vascular endothelial growth factor expression under ischemic stress in human meningiomas. Neurosci Lett 283 (2000) 45-48
171. Lamszus K., Lengler U., Schmidt N.O., et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46 (2000) 938-947
172. Lutchman M., and Rouleau G.A. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res 55 (1995) 2270-2274
173. Sherman L., Xu H.M., Geist R.T., et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15 (1997) 2505-2509
174. Schrell U.M., Koch H.U., Marschalek R., et al. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M. J Neurosurg 88 (1998) 541-548
175. Jaffrain-Rea M.L., Minniti G., Santoro A., et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg 100 (1998) 40-43
176. Prat R., Banzo J., and Diaz F.J. Somatostatin receptors in meningioma: diagnostic and therapeutic value. Rev Neurol 25 (1997) 2002-2005
177. Friend K.E., Radinsky R., and McCutcheon I.E. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 91 (1999) 93-99
178. McCutcheon I.E., Flyvbjerg A., Hill H., et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94 (2001) 487-492
179. Corn B.W., Yousem D.M., Scott C.B., et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer 74 (1994) 2828-2835
180. Crossen J.R., Garwood D., Glatstein E., and Neuwelt E.A. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12 (1994) 627-642
181. Kumar A.J., Leeds N.E., Fuller G.N., et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217 (2000) 377-384
182. Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360 (2002) 1361-1368
183. Gregor A., Cull A., Traynor E., et al. Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol 41 (1996) 55-59
184. Brandes A.A., Pasetto L.M., Lumachi F., and Monfardini S. Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management. J Neurooncol 47 (2000) 85-92